{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:59:59Z","timestamp":1785272399209,"version":"3.55.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2026,4]]},"DOI":"10.2967\/jnumed.125.270677","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:10:19Z","timestamp":1769706619000},"page":"568-575","source":"Crossref","is-referenced-by-count":1,"title":["PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [\n                    <sup>225<\/sup>\n                    Ac]Ac-PSMA Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"67","author":[{"given":"Liam","family":"Widjaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz J.","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Wenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026040105551060000_67.4.568.1","doi-asserted-by":"crossref","first-page":"1468357","DOI":"10.3389\/fonc.2024.1468357","article-title":"Editorial: theranostics as a driving force in nuclear medicine","volume":"14","author":"Rowe","year":"2024","journal-title":"Front Oncol."},{"key":"2026040105551060000_67.4.568.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026040105551060000_67.4.568.3","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2026040105551060000_67.4.568.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026040105551060000_67.4.568.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2026040105551060000_67.4.568.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"2026040105551060000_67.4.568.7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026040105551060000_67.4.568.8","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.7150\/thno.106574","article-title":"Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis","volume":"15","author":"Ninatti","year":"2025","journal-title":"Theranostics."},{"key":"2026040105551060000_67.4.568.9","unstructured":"FDA expands Pluvictos metastatic castration-resistant prostate cancer indication; 28.03.2025. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Updated March 28, 2025. Accessed January 13, 2026."},{"key":"2026040105551060000_67.4.568.10","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/biomedicines10050946","article-title":"Total tumor volume on 18F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with 225Ac-PSMA-I&T","volume":"10","author":"Unterrainer","year":"2022","journal-title":"Biomedicines."},{"key":"2026040105551060000_67.4.568.12","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers13122938","article-title":"PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under 177Lu-PSMA-617 radioligand therapy","volume":"13","author":"Widjaja","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026040105551060000_67.4.568.13","doi-asserted-by":"crossref","first-page":"663631","DOI":"10.3389\/fonc.2021.663631","article-title":"Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET\/CT imaging in prostate cancer patients","volume":"11","author":"Mittlmeier","year":"2021","journal-title":"Front Oncol."},{"key":"2026040105551060000_67.4.568.14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026040105551060000_67.4.568.16","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2026040105551060000_67.4.568.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265546"},{"key":"2026040105551060000_67.4.568.18","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","article-title":"Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review","volume":"48","author":"Manafi-Farid","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.19","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2026040105551060000_67.4.568.20","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1007\/s00259-025-07323-x","article-title":"PET imaging utilization and trends in Germany: a comprehensive survey","volume":"52","author":"Holzgreve","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269319"},{"key":"2026040105551060000_67.4.568.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1390-8"},{"key":"2026040105551060000_67.4.568.23","first-page":"660","article-title":"Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET\/CT: initial experience with the keyhole approach","volume":"11","author":"Hartrampf","year":"2022","journal-title":"Biology (Basel)."},{"key":"2026040105551060000_67.4.568.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.241588"},{"key":"2026040105551060000_67.4.568.25","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1038\/s41598-024-61961-z","article-title":"Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT","volume":"14","author":"Rosar","year":"2024","journal-title":"Sci Rep."},{"key":"2026040105551060000_67.4.568.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026040105551060000_67.4.568.27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-019-04317-4","article-title":"DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA","volume":"46","author":"Schumann","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","article-title":"Individual radiosensitivity reflected by gamma-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy","volume":"50","author":"Widjaja","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026040105551060000_67.4.568.29","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:17:49Z","timestamp":1785269869000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.2967\/jnumed.125.270677"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270677","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}